Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | CTSB | P07858 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 1/20 | 0.53 |
| ▸ | CTSK | P43235 | 1/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 5/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.52 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | ECE1 | P42892 | 1/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16485550 | 1.00 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL18224217 | 1.00 | CTSL (0.53) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL330061 | 0.97 | CTSL (0.55) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL5486969 | 0.97 | CTSL (0.55) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL8976911 | 0.97 | CTSL (0.55) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL9333779 | 0.95 | MME (0.54) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL19065177 | 0.93 | MME (0.56) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL13588070 | 0.93 | MME (0.56) | CTSLCTSBCTSSCTSKITGB3 | |
| SCHEMBL27829774 | 0.93 | CTSL (0.57) | CTSLCTSBCTSSCTSKTACR1 | |
| SCHEMBL31650945 | 0.92 | ACE (0.56) | CTSLCTSBCTSSCTSKTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098440-A1 | BISPECIFIC ANTIBODY CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海齐鲁制药研究中心有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4714956-A2 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | Daiichi Sankyo Company, Limited (JP) | 2026-03-25 | — | — | EP | disclosed |
| US-12503489-B2 | Method for producing antibody-drug conjugate | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-12-23 | — | — | US | disclosed |
| EP-3677589-B1 | IMPROVED METHOD FOR PRODUCING ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO CO LTD (JP) | 2025-11-26 | — | — | EP | disclosed |
| EP-4595979-A1 | AURISTATIN DRUG WITH HIGH-STABILITY HYDROPHILIC LINKING UNIT AND CONJUGATE THEREOF | SystImmune, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2025151685-A1 | ANTIBODY-AURISTATIN DRUG CONJUGATE AND PHARMACEUTICAL USE THEREOF | SYSTIMMUNE, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2025151684-A1 | ANTIBODY-AURISTATIN DRUG CONJUGATES AND METHODS OF MAKING AND USING THEREOF | SYSTIMMUNE, INC. (US) | 2025-07-17 | — | — | WO | disclosed |
| WO-2024235128-A9 | ANTIBODY-DRUG CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| WO-2024235132-A9 | COMPOUND HAVING BIOLOGICAL ACTIVITY, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-06-19 | — | — | WO | disclosed |
| US-20160333112-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-11-17 | — | — | US | disclosed |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-09-29 | — | — | US | disclosed |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-10-22 | — | — | US | disclosed |
| EP-2907824-A1 | ANTIBODY-DRUG CONJUGATE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-08-19 | — | — | EP | disclosed |
| US-4350628-A | OXIDATIVE DEHYDROGENATION WITH A BENZOQUINONE | RESEARCH CORPORATION (US) | 1982-09-21 | — | — | US | disclosed |
| US-4283328-A | TREATING AN N-BLOCKED AMINO ACID RESIDUE WITH A TETRAMETHYL GUANIDINIUM SALT OF A PEPTIDE CHAIN | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
| US-4261884-A | DESIRABLE BIOLOGICAL PROPERTIES AND STABILITY TO ENZYME CLEAVAGE | RESEARCH CORPORATION (US) | 1981-04-14 | — | — | US | disclosed |
| EP-0010830-A2 | Dehydropeptides | Research Corporation (US) | 1980-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12370263-B2 | Cyclic dinucleotide derivative based antibody-drug conjugates | STING1, CGAS, CDA | CTSL 4256/4885CTSB 2033/4885CTSS 3687/4885 |
| US-20160333112-A1 | ANTI-HER2 ANTIBODY-DRUG CONJUGATE | ERBB2, EGFR, H1-2 | CTSL 401/4885CTSB 1197/4885CTSS 2199/4885 |
| US-12503489-B2 | Method for producing antibody-drug conjugate | UGT1A9, ALB, MRPL21 | CTSL 2137/4885CTSB 1278/4885CTSS 2243/4885 |
| US-20160279259-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | CTSL 163/4885CTSB 1411/4885CTSS 2696/4885 |
| US-20150297748-A1 | ANTIBODY-DRUG CONJUGATE | LANCL2, LANCL1, LCLAT1 | CTSL 163/4885CTSB 1411/4885CTSS 2696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.